Discover how RVD therapy for multiple myeloma is being optimized to reduce costs, decrease clinic time, and maintain patient safety through innovative approaches.
Exploring the promising combination of daratumumab and pembrolizumab as immunotherapy for refractory multiple myeloma in a phase 2 clinical trial.
Explore how daratumumab enables in vivo purging to cleanse stem cell grafts before transplant, reducing relapse risk in multiple myeloma patients.
Exploring real-world treatment patterns and outcomes for multiple myeloma patients in the US, focusing on how patient characteristics influence therapeutic decisions and survival.
Exploring how next-generation sequencing and flow cytometry are transforming minimal residual disease detection in multiple myeloma treatment.